Cover image of the article: Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leader’s Meeting-28th July 2011-Tehran, IR Iran

Image Credit:Hepat Mon

Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leader’s Meeting-28th July 2011-Tehran, IR Iran

Authors

Seyed Moayed Alavian1,*, Kamran B Lankarani2, Seyed Hossein Aalaei-Andabili1, Ali Pouryasin3, Nasser Daryani4, Mohsen Nasiritoosi4, Reza Malekzadeh5, Mohammad Reza Zali6, Mino Mohraz7
1Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
3Islamic Azad University, Arsanjan Branch, Basic Science Faculty, Biology Department, Arsanjan, IR Iran
4Tehran University of Medical Sciences, Tehran, IR Iran
5Digestive Disease Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
6Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran,, IR Iran
7Iranian Research Center for HIV/AIDS (IRCHA), Tehran University of Medical Sciences, Tehran, IR Iran
*Corresponding Author: Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran Email: alavian@thc.ir

Hepatitis Monthly:Vol. 11, issue 9; e93018
Published online:Sep 30, 2011
Article type:Review Article
Received:May 06, 2019
Accepted:Sep 30, 2011
How to Cite:Alavian SM, B Lankarani K, Aalaei-Andabili SH, Pouryasin A, Daryani N, et al. Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leader’s Meeting-28th July 2011-Tehran, IR Iran. Hepat Mon. 2011;11(9):e93018. doi:

Abstract

Complete name and affiliation of collaborators are listed at the end of this article as an Appendix ( page: 711 ). 

Hepatitis C remains as an important health problem worldwide. Hepatitis C treatment, especially among patients infected with HCV genotype 1 who are considered difficult to treat, is a high priority for health policy-makers. PegInterferon alfa instead of Interferon and ribavirin combination therapy has been accepted as the standard treatment regimen for hepatitis C patients; however, only 50% of patients infected with HCV genotype 1 achieve a sustained virological response. Published data from various clinical trials of protease inhibitors suggest that new therapeutic regimens may increase the chances of a successful response in patients infected with HCV genotype 1. Triple therapy that includes boceprevir has been shown to result in high rates of sustained virological response in both naive and experienced patients with HCV genotype 1 infection. In this review, we have summarized the results obtained with this new regimen and have attempted to provide a guideline for the treatment of patients in Iran, with emphasis on cost and the occurrence of adverse events.

Implication for health policy/practice/research/medical education: 
Proper treatment of hepatitis C to control the burden of disease is essential in the society. Nowadays with the new methods of therapy the hope of eradication is more than before. This study is recommended to internal medicine and infectious disease specialists, gastroenterologists, general practitioners, virologists and health policy makers.

Please cite this paper as:
Alavian SM, Lankarani KB, Aalaei-Andabili SH, Pouryasin A, Ebrahimi Daryani N, Nassiri Toosi M, et al. Treatment of Chronic Hepatitis C Infection: Updated of the Recommendations from Scientific Leaders' Meeting-28th July 2011-Tehran, IR Iran. Hepat Mon. 2011; 11(9):703-13. DOI: 10.5812/kowsar.1735143X.769

Highlights

References

  • 1.
    The references are available in the PDF file.

Copyright

© 2011, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

31
Jul
2012
Hepatitis C Virus: The Rising Concerns and Growing Hopes, Report From the HCV Symposium, Fourth Tehran Hepatitis Congress, november 2011, Tehran, Iran

Hepatitis C Virus: The Rising Concerns and Growing Hopes, Report From the HCV Symposium, Fourth Tehran Hepatitis Congress, november 2011, Tehran, Iran

Seyed Moayed Alavian,
Hossain Jabbari,
Nasser Ebrahimi Daryani,
Mohammad Torabi Nami

Alavian SM, Jabbari H, Ebrahimi Daryani N, Torabi Nami M. Hepatitis C Virus: The Rising Concerns and Growing Hopes, Report From the HCV Symposium, Fourth Tehran Hepatitis Congress, november 2011, Tehran, Iran. Hepat Mon. 2012;12(7):. doi: https://doi.org/10.5812/hepatmon.6679

13
Aug
2016
Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline

Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline

Seyed Moayed Alavian,
Behzad Hajarizadeh,
Kamran Bagheri Lankarani,
Heidar Sharafi,
Nasser Ebrahimi Daryani,
Shahin Merat
,et al.

Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, et al. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016;16(8):e40959. doi: https://doi.org/10.5812/hepatmon.guideline

20
Nov
2017
Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017

Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017

Seyed Moayed Alavian,
Heidar Sharafi

Alavian SM, Sharafi H. Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017. Hepat Mon. 2017;17(11):e63956. doi: https://doi.org/10.5812/hepatmon.63956

20
Nov
2013
Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013

Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013

Nasser Ebrahimi Daryani,
Seyed Moayed Alavian,
Mohammad Hossein Somi,
Mohammad Torabi-Nami

Ebrahimi Daryani N, Alavian SM, Somi MH, Torabi-Nami M. Hepatitis C and Why the Treatment is Needed Now? The Summary Report From the Cross-Border Symposium of the 5th Tehran Hepatitis Congress May 2013. Hepat Mon. 2013;13(11):e16082. doi: https://doi.org/10.5812/hepatmon.16082

1
Oct
2009
Epidemiology of Hepatitis C in Iran and the World.

Epidemiology of Hepatitis C in Iran and the World.

SM Alavian,
F Fallahian

Alavian S, Fallahian F. Epidemiology of Hepatitis C in Iran and the World.. Shiraz E-Med J. 2009;10(4):. doi:

More by these authors

Seyed Moayed AlavianPubMedScholar
Kamran B LankaraniPubMedScholar
Seyed Hossein Aalaei-AndabiliPubMedScholar
Ali PouryasinPubMedScholar
Nasser DaryaniPubMedScholar
Mohsen NasiritoosiPubMedScholar
Reza MalekzadehPubMedScholar
Mohammad Reza ZaliPubMedScholar
Mino MohrazPubMedScholar
Share
Cited by
Metrics